Cantor Fitzgerald Forecasts ARCT FY2026 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Arcturus Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the biotechnology company will post earnings per share of ($3.06) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.22) per share.

Several other research firms also recently commented on ARCT. Canaccord Genuity Group dropped their price objective on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the company a "buy" rating in a research note on Monday, March 10th. Citigroup reaffirmed a "buy" rating on shares of Arcturus Therapeutics in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Finally, Scotiabank started coverage on shares of Arcturus Therapeutics in a report on Wednesday, May 28th. They issued a "sector outperform" rating and a $32.00 price target for the company. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $53.50.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock traded up $0.36 on Tuesday, reaching $12.90. 657,898 shares of the company traded hands, compared to its average volume of 442,685. The company has a 50 day moving average of $11.49 and a 200 day moving average of $14.54. Arcturus Therapeutics has a 52 week low of $8.04 and a 52 week high of $34.17. The firm has a market capitalization of $349.86 million, a PE ratio of -5.81 and a beta of 2.30.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. The firm had revenue of $29.38 million during the quarter, compared to the consensus estimate of $25.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently added to or reduced their stakes in ARCT. Byrne Asset Management LLC boosted its holdings in shares of Arcturus Therapeutics by 89.8% in the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 1,365 shares in the last quarter. US Bancorp DE lifted its position in Arcturus Therapeutics by 218.9% in the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock worth $36,000 after buying an additional 2,329 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after buying an additional 1,132 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Arcturus Therapeutics during the fourth quarter valued at approximately $71,000. Finally, GAMMA Investing LLC raised its stake in shares of Arcturus Therapeutics by 3,482.9% during the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock worth $550,000 after acquiring an additional 5,085 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.